Based on focus groups with children and young people with peanut allergy, experts have published guidance for clinicians working in the UK’s National Health Service (NHS) to help them safely and equitably implement Palforzia® peanut oral immunotherapy. Their recommendations are published in Clinical & Experimental Allergy.
Based on focus groups with children and young people with peanut allergy, experts have published guidance for clinicians working in the UK’s National Health Service (NHS) to help them safely and equitably implement Palforzia® peanut oral immunotherapy. Their recommendations are published in Clinical & Experimental Allergy.
In 2022, the National Institute for Health and Care Excellence in the UK recommended the use of Palforzia®—which has defatted peanut powder as its active ingredient—for desensitizing children and young people with peanut allergy in the NHS.
The new consensus guidance will inform and support healthcare professionals as they implement Palforzia® for desensitization and as they gradually increase peanut dosing in patients.
“It is great we can now offer an actual treatment for peanut allergy, rather than just recommend avoidance and educate patients on how to recognize and manage reactions, but the challenge in our current NHS is how we can provide this to eligible patients equitably, regardless of where they live and their backgrounds,” said corresponding author Tom Marrs, PhD, of Guy’s and St Thomas’ NHS Foundation Trust. “This guidance outlines what NHS services need to be able to offer this treatment at scale and to advocate for patients so that we can develop best-practice models.”
Additional Information
NOTE: The information contained in this release is protected by copyright. Please include journal attribution in all coverage. For more information or to obtain a PDF of any study, please contact: Sara Henning-Stout, newsroom@wiley.com.
About the Journal
Clinical & Experimental Allergy is the Official Journal of the British Society for Allergy & Clinical Immunology, publishing clinical and experimental observations in disease in all fields of medicine in which allergic hypersensitivity plays a part.Clinical & Experimental Allergy strikes an excellent balance between clinical and scientific articles and carries regular reviews and editorials written by leading authorities in their field.
About Wiley
Wiley is a knowledge company and a global leader in research, publishing, and knowledge solutions. Dedicated to the creation and application of knowledge, Wiley serves the world’s researchers, learners, innovators, and leaders, helping them achieve their goals and solve the world’s most important challenges. For more than two centuries, Wiley has been delivering on its timeless mission to unlock human potential. Visit us at Wiley.com. Follow us on Facebook, Twitter, LinkedIn and Instagram.
Journal
Clinical & Experimental Allergy
Article Title
BSACI Guidance for the Implementation of Palforzia® Peanut Oral Immunotherapy in the United Kingdom: a Delphi Consensus Study
Article Publication Date
26-Jun-2024
